Ahmed Shazia, Singh Aman, Krauss John, Wentz Tracey, Gunaratnam Naresh T
Department of Internal Medicine, St. Joseph Mercy Hospital, Ann Arbor, Michigan 48195, USA.
Am J Clin Oncol. 2003 Aug;26(4):408-10. doi: 10.1097/01.COC.0000026485.57632.1E.
Duodenal lymphoma accounts for a small percentage of gastrointestinal tumors and has a very poor prognosis. The majority of patients have little or no cure with limited time of remission. Median survival is 5 to 10 years, and most patients die of lymphoma, its complications, or complications of therapy. We report a patient with lymphoma refractory to treatment with cyclophosphamide, vincristine, and prednisone, who was successfully treated with rituximab, a CD-20 monoclonal antibody.
十二指肠淋巴瘤在胃肠道肿瘤中占比很小，预后很差。大多数患者几乎无法治愈或治愈希望渺茫，缓解期有限。中位生存期为5至10年，大多数患者死于淋巴瘤、其并发症或治疗并发症。我们报告了一名对环磷酰胺、长春新碱和泼尼松治疗无效的淋巴瘤患者，该患者用CD-20单克隆抗体利妥昔单抗成功治愈。
